This is the authors' abstract. We don't add key points for this paper.
IN the preceding papers of this series, the background and laboratory development of a live attenuated measles virus and its first clinical trials as a vaccinating agent have been described by the responsible workers. In this final paper representatives of the participating groups have attempted to summarize and evaluate the data obtained and to offer from this experience suggestions for future study and use of measles vaccine (attenuated).ResultsAlthough the experimental design varied somewhat in each group, the results were strikingly similar. A total of 303 children received the vaccine. Thirty-one of them were vaccinated orally, intranasally or via . . .
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Katz et al. (1960) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: